<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342886</url>
  </required_header>
  <id_info>
    <org_study_id>NC-006-(M-PA-Z)</org_study_id>
    <nct_id>NCT02342886</nct_id>
  </id_info>
  <brief_title>Shortening Treatment by Advancing Novel Drugs</brief_title>
  <acronym>STAND</acronym>
  <official_title>A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 4 and 6 Months of Treatment in Adult Subjects With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and After 6 Months of Treatment in Adult Subjects With Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Alliance for TB Drug Development</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Alliance for TB Drug Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, safety and tolerability of a combination
      of moxifloxacin, PA-824, and pyrazinamide treatments with varying doses and treatment lengths
      from 4 to 6 months in subjects with drug-sensitive (DS) pulmonary TB compared to standard
      HRZE treatment.

      This study will also assess the efficacy, safety and tolerability of a combination of
      moxifloxacin, PA-824, and pyrazinamide treatments after 6 months of treatment in subjects
      with multi drug-resistant (MDR) pulmonary TB compared to a combination of moxifloxacin,
      PA-824, and pyrazinamide treatments in DS-TB subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population)</measure>
    <time_frame>From Day 1 to Month 12.</time_frame>
    <description>Patients were classified as having a favorable, unfavorable or unassessable status at 12 months from the start of therapy.
A favourable status was a negative culture status at 12 months from start of therapy in patients who had not already been classified as having an unfavorable outcome, and whose last positive culture result was followed by at least 2 negative culture results. Patients with an unfavorable status did not achieve/maintain culture negative status, or previously had culture negative status who following end of treatment (EOT), had 2 positive cultures, or had a positive culture not followed by 2 negative cultures, or were dying from any cause during treatment (except accidental cause not including suicide), or were dying from TB related causes during follow-up, or required an extension, restart or change of treatment except for reinfection/pregnancy, or failed to complete adequate treatment who were unassessable at 12 months or lost to follow-up/withdrawn before EOT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population)</measure>
    <time_frame>From Day 1 to Month 12.</time_frame>
    <description>Patients were classified as having a favorable, unfavorable or unassessable status at 12 months from the start of therapy.
A favourable status was a negative culture status at 12 months from start of therapy in patients who had not already been classified as having an unfavorable outcome, and whose last positive culture result was followed by at least 2 negative culture results. Patients with an unfavorable status did not achieve/maintain culture negative status, or previously had culture negative status who following EOT, had 2 positive cultures, or had a positive culture not followed by 2 negative cultures, or died from any cause during treatment (except accidental cause not including suicide), or were dying from TB related causes during follow-up, or required a restart or change of treatment because of an unfavorable outcome with or without bacteriological confirmation, ie, on bacteriological, radiographic or clinical grounds.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">284</enrollment>
  <condition>Tuberculosis, Pulmonary, Drug Sensitive</condition>
  <condition>Tuberculosis, Pulmonary, Multi Drug-resistant</condition>
  <arm_group>
    <arm_group_label>MDR-TB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-TB (HRZE), HR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>26 consecutive weeks to DS-TB subjects only, as follows:
HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) Weeks 1-8 with daily dose per the subjects weight
HR (Rifampicin plus isoniazid combination tablets) Weeks 9 - 26 with daily dose per the subjects weight
Daily dose per the subjects weight as follows: 30-39kg: 2 tablets; 40-54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-TB PA-824 200mg 26 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once daily for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-TB PA-824 200mg 17 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once a day for 17 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-TB PA-824 100mg 17 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moxifloxacin 400 mg + PA-824 100 mg + pyrazinamide 1500 mg orally once daily for 17 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Oral</description>
    <arm_group_label>DS-TB PA-824 100mg 17 weeks</arm_group_label>
    <arm_group_label>DS-TB PA-824 200mg 17 weeks</arm_group_label>
    <arm_group_label>DS-TB PA-824 200mg 26 weeks</arm_group_label>
    <arm_group_label>MDR-TB</arm_group_label>
    <other_name>BAY 12-8039</other_name>
    <other_name>Avelox</other_name>
    <other_name>Avalon</other_name>
    <other_name>Avelon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PA-824</intervention_name>
    <description>Oral</description>
    <arm_group_label>DS-TB PA-824 100mg 17 weeks</arm_group_label>
    <arm_group_label>DS-TB PA-824 200mg 17 weeks</arm_group_label>
    <arm_group_label>DS-TB PA-824 200mg 26 weeks</arm_group_label>
    <arm_group_label>MDR-TB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
    <description>Oral</description>
    <arm_group_label>DS-TB PA-824 100mg 17 weeks</arm_group_label>
    <arm_group_label>DS-TB PA-824 200mg 17 weeks</arm_group_label>
    <arm_group_label>DS-TB PA-824 200mg 26 weeks</arm_group_label>
    <arm_group_label>MDR-TB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)</intervention_name>
    <description>Oral</description>
    <arm_group_label>DS-TB (HRZE), HR</arm_group_label>
    <other_name>Rifafour e-275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR (rifampicin plus isoniazid combination tablets)</intervention_name>
    <description>Oral</description>
    <arm_group_label>DS-TB (HRZE), HR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written consent or witnessed oral consent in the case of illiteracy, prior to
             undertaking any trial-related procedures.

          2. Male or female, aged 18 years or over.

          3. Body weight (in light clothing and no shoes) ≥ 30 kg.

          4. Sputum positive for tubercule bacilli (at least 1+ on the International Union Against
             Tuberculosis and Lung Disease (IUATLD) and World Health Organization (WHO) scale on
             smear microscopy at the trial laboratory.

          5. Drug‐Sensitive TB treatment arms subjects should be:

               -  sensitive to rifampicin by rapid sputum based test (may be sensitive or resistant
                  to isoniazid) AND

               -  either newly diagnosed for TB or have a patient history of being untreated for at
                  least 3 years after cure from a previous episode of TB. If they are entered into
                  the trial due to being sensitive to rifampicin by rapid sputum based test,
                  however on receipt of the rifampicin resistance testing using an indirect
                  susceptibility test in liquid culture this shows they are rifampicin resistant,
                  they will be:

               -  Excluded as late exclusions;

               -  Possibly replaced as determined by the sponsor.

          6. MDR‐TB treatment arm subjects should be resistant to rifampicin by rapid sputum based
             test (may be sensitive or resistant to isoniazid).

          7. A chest x-ray which in the opinion of the investigator is compatible with pulmonary
             TB.

          8. Be of non‐childbearing potential or using effective methods of birth control, as
             defined below:

        Non‐childbearing potential:

          -  Subject ‐ not heterosexually active or practice sexual abstinence; or

          -  Female subject or male subjects female sexual partner ‐ bilateral oophorectomy,
             bilateral tubal ligation and/or hysterectomy or has been postmenopausal with a history
             of no menses for at least 12 consecutive months; or

          -  Male subject or female subjects male sexual partner ‐ vasectomised or has had a
             bilateral orchidectomy minimally three months prior to screening;

        Effective birth control methods:

          -  Double barrier method which can include a male condom, diaphragm, cervical cap, or
             female condom; or

          -  Female subject: Barrier method combined with hormone‐based contraceptives or an
             intra‐uterine device for the female patient.

          -  Male subjects' female sexual partner: Double barrier method or hormone‐based
             contraceptives or an intra‐uterine device for the female partner.

        and are willing to continue practising birth control methods and are not planning to
        conceive throughout treatment and for 12 weeks (male subjects) or 1 week (female subjects)
        after the last dose of trial medication or discontinuation from trial medication in case of
        premature discontinuation.

        (Note: Hormone‐based contraception alone may not be reliable when taking IMP; therefore,

        Exclusion Criteria:

          1. Any non TB related condition (including myasthenia gravis) where participation in the
             trial, as judged by the investigator, could compromise the well-being of the subject
             or prevent, limit or confound protocol specified assessments.

          2. Being or about to be treated for Malaria.

          3. Is critically ill and, in the judgment of the investigator, has a diagnosis likely to
             result in death during the trial or the follow-up period.

          4. TB meningitis or other forms of extrapulmonary tuberculosis with high risk of a poor
             outcome, or likely to require a longer course of therapy (such as TB of the bone or
             joint), as judged by the investigator.

          5. History of allergy or hypersensitivity to any of the trial IMP or related substances,
             including known allergy to any fluoroquinolone antibiotic, history of tendinopathy
             associated with quinolones or suspected hypersensitivity to any rifampicin
             antibiotics.

          6. For HIV infected subjects any of the following:

               -  CD4+ count &lt;100 cells/µL;

               -  Karnofsky score &lt;60%;

               -  Received intravenous antifungal medication within the last 90 days;

               -  WHO Clinical Stage 4 HIV disease.

          7. Resistant to fluoroquinolones (rapid, sputum - based molecular screening tests). If
             they are entered into the trial due to being sensitive to fluoroquinolones by rapid
             sputum based test, however on receipt of the fluoroquinolones resistance testing using
             an indirect susceptibility test in liquid culture this shows they are fluoroquinolones
             resistant, they will be:

               -  Excluded as late exclusions;

               -  Possibly replaced as determined by the sponsor.

          8. Resistant to pyrazinamide (rapid, sputum - based molecular screening tests).

             Drug-Sensitive TB treatment arms subjects may be entered prior to receipt of the
             rapid, sputum - based molecular pyrazinamide resistance screening test result. On
             receipt of the result, if they are resistant, they will be:

               -  Excluded as late exclusions;

               -  Possibly replaced as determined by the sponsor. MDR-TB treatment arm subjects may
                  not be entered prior to receipt of the rapid, sputum - based molecular
                  pyrazinamide resistance screening test result showing they are sensitive to
                  pyrazinamide.

          9. Having participated in other clinical trials with investigational agents within 8
             weeks prior to trial start or currently enrolled in an investigational trial.

         10. Subjects with any of the following at screening (per measurements and reading done by
             Central Electrocardiogram (ECG) where applicable):

               -  Cardiac arrhythmia requiring medication;

               -  Prolongation of QT/QTc interval with QTcF (Fridericia correction) &gt;450 ms;

               -  History of additional risk factors for Torsade de Pointes, (e.g., heart failure,
                  hypokalemia, family history of Long QT Syndrome);

               -  Any clinically significant ECG abnormality, in the opinion of the investigator.

         11. Unstable Diabetes Mellitus which required hospitalization for hyper- or hypo-glycaemia
             within the past year prior to start of screening.

             Specific Treatments

         12. Previous treatment with PA-824 as part of a clinical trial.

         13. For DS-TB treatment arms: Previous treatment for tuberculosis within 3 years prior to
             Day (-9 to -1)(Screening). Subjects who have previously received isoniazid
             prophylactically may be included in the trial as long as that treatment is/was
             discontinued at least 7 days prior to randomization into this trial.

             For the MDR-TB Subjects: Previous treatment for MDR-TB, although may have been on a
             MDR TB treatment regimen for no longer than 7 days at start of screening.

             Previous treatment for TB includes, but is not limited to, gatifloxacin, amikacin,
             cycloserine, rifabutin, kanamycin, para-aminosalicylic acid, rifapentine,
             thioacetazone, capreomycin, quinolones, thioamides, and metronidazole.

         14. Any diseases or conditions in which the use of the standard TB drugs or any of their
             components is contra-indicated, including but not limited to allergy to any TB drug,
             their component or to the IMP.

         15. Use of any drug within 30 days prior to randomisation known to prolong QTc interval
             (including, but not limited to, amiodarone, amitriptyline, bepridil, chloroquine,
             chlorpromazine, cisapride, clarithromycin, disopyramide dofetilide, domperidone,
             droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl,
             mesoridazine, methadone, pentamidine, pimozide, procainamide, quinacrine, quinidine,
             sotalol, sparfloxacin, thioridazine).

         16. Use of systemic glucocorticoids within one year of start of screening (inhaled or
             intranasal glucocorticoids are allowed).

         17. Subjects recently started or expected to need to start anti-retroviral therapy (ART)
             within 1 month after randomization. Subjects may be included who have been on ARTs for
             greater than 30 days prior to start of screening, or who are expected to start ART
             greater than 30 days after randomization.

             Laboratory Abnormalities

         18. Subjects with the following toxicities at screening as defined by the enhanced
             Division of Microbiology and Infectious Disease (DMID) adult toxicity table (November
             2007), where applicable:

               -  creatinine grade 2 or greater (&gt;1.5 times upper limit of normal [ULN]);

               -  creatinine clearance (CrCl) level less than 30 mLs/min according to the
                  Cockcroft-Gault Formula;

               -  haemoglobin grade 4 (&lt;6.5 g/dL);

               -  platelets grade 3 or greater (under 50x109 cells/L/ 50 000/mm3);

               -  serum potassium less than the lower limit of normal for the laboratory. This may
                  be repeated once;

               -  aspartate aminotransferase (AST) grade 3 or greater (≥3.0 x ULN) ;

               -  alanine aminotransferase (ALT) grade 3 or greater (≥3.0 x ULN);

               -  alkaline phosphatase (ALP):

                    -  grade 4 (&gt;8.0 x ULN) to be excluded;

                    -  grade 3 (≥3.0 - 8.0 x ULN) must be discussed with and approved by the
                       sponsor Medical Monitor;

               -  total bilirubin:

                    -  2.0 x ULN, when other liver functions are in the normal range

                    -  1.50 x ULN when accompanied by any increase in other liver function tests
                       subjects with total bilirubin &gt; 1.25 x ULN and accompanied by any increase
                       in other liver function tests must be discussed with the sponsor medical
                       monitor before enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen H Gillespie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of St Andrews</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center for Tuberculosis and Lung Diseases</name>
      <address>
        <city>Tbilisi</city>
        <zip>0101</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Respiratory Disease Research (CRDR) Keny Medical Research Institute (KEMRI)</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Respiratory Disease Research (CRDR) Kenya Medical Research Institute (KEMRI)</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusat Perubatan Universiti Kebangsaan</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universiti Teknologi MARA</name>
      <address>
        <city>Batu Caves</city>
        <state>Selangor</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Respiratory Medicine (IPR)</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>53000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Ermita</city>
        <state>Manila</state>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vincent Balang</name>
      <address>
        <city>Pio del Pilar</city>
        <state>Manila</state>
        <zip>1230</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung Center of Philippines</name>
      <address>
        <city>Manila</city>
        <zip>1104</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TASK</name>
      <address>
        <city>Bellville</city>
        <state>Cape Town</state>
        <zip>7531</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cape Town Lung Institute</name>
      <address>
        <city>Mowbray</city>
        <state>Cape Town</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute: Tembisa Hospital Cnr</name>
      <address>
        <city>Tembisa</city>
        <state>Gauteng</state>
        <zip>1632</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Themba Lethu Clinic</name>
      <address>
        <city>Westdene</city>
        <state>Johannesburg</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durban International Clinical Trials Unit (DbnlCTU)</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klerksdorp Tshepong Hospital</name>
      <address>
        <city>Klerksdorp</city>
        <state>North West Province</state>
        <zip>2571</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus SA</name>
      <address>
        <city>Mamelodi East</city>
        <state>Pretoria</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madibeng Centre for Research (MCR)</name>
      <address>
        <city>Brits</city>
        <zip>0250</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>THINK: Tuberculosis &amp; HIV Investigative Network of Kwazulu Natal</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute</name>
      <address>
        <city>Klerksdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute: Rustenberg</name>
      <address>
        <city>Rustenburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ifakara Health Institute (IHI)</name>
      <address>
        <city>Dar es Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIMR - Mbeya Medical Research Programme (MMRP)</name>
      <address>
        <city>Mbeya</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilimanjaro National Institute for Medical Research</name>
      <address>
        <city>Mwanza</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uganda CWRU Research Collaboration</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Infectious Disease Research in Zambia (CIDRZ)</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Kenya</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>Uganda</country>
    <country>Zambia</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>China</country>
    <country>Haiti</country>
    <country>Mozambique</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>Thailand</country>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2015</study_first_posted>
  <results_first_submitted>February 2, 2019</results_first_submitted>
  <results_first_submitted_qc>March 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2019</results_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Multi Drug-Resistant Tuberculosis</keyword>
  <keyword>Drug-sensitive Tuberculosis</keyword>
  <keyword>PA-824</keyword>
  <keyword>Moxifloxacin</keyword>
  <keyword>Pyrazinamide</keyword>
  <keyword>Rifampicin</keyword>
  <keyword>Isoniazid</keyword>
  <keyword>Ethambutol</keyword>
  <keyword>HRZE</keyword>
  <keyword>HR</keyword>
  <keyword>Pretomanid</keyword>
  <keyword>NC-006</keyword>
  <keyword>STAND</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 14, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02342886/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02342886/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult male and female patients with drug-sensitive (DS) and multi-drug resistant (MDR) smear-positive pulmonary tuberculosis (TB) were recruited into this open-label multicenter study.</recruitment_details>
      <pre_assignment_details>Patients were confirmed sputum positive for tubercule bacilli on smear microscopy. DS-TB patients were required to be sensitive to rifampicin and newly diagnosed with pulmonary TB (or untreated for at least 3 years). MDR-TB patients were required to be resistant to rifampicin. Both DS and MDR-TB patients could be sensitive/resistant to isoniazid.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide</title>
          <description>Patients with DS-TB were randomized to receive 400 milligrams (mg) moxifloxacin + 100 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 4 months during the treatment period (from Day 1 to Week 17). Patients then entered a follow-up period up to Month 24.</description>
        </group>
        <group group_id="P2">
          <title>DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
          <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 4 months during the treatment period (from Day 1 to Week 17). Patients then entered a follow-up period up to Month 24.</description>
        </group>
        <group group_id="P3">
          <title>DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
          <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 6 months during the treatment period (from Day 1 to Week 26). Patients then entered a follow-up period up to Month 24.</description>
        </group>
        <group group_id="P4">
          <title>DS-TB: 2 Months HRZE / 4 Months HR</title>
          <description>Patients with DS-TB were randomized to receive 150 mg rifampicin + 75 mg isoniazid + 400 mg pyrazinamide + 275 mg ethambutol combination tablets (HRZE) orally once daily from Weeks 1 to 8 during the treatment period. Patients then received 150 mg rifiampicin + 75 mg isoniazid combination tablets (HR) orally once daily from Weeks 9 to 26 during the treatment period. The daily dose of HRZE and HR was calculated based on patients' weight. Patients then entered a follow-up period up to Month 24.</description>
        </group>
        <group group_id="P5">
          <title>MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
          <description>Patients with MDR-TB received 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 6 months during the treatment period (from Day 1 to Week 26). Patients then entered a follow-up period up to Month 24.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="68"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Month 12 Follow-Up</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="57"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Month 24 Follow-Up</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="53"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="59"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Treatment non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Late exclusion: rifampicin resistance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event/specific toxicity</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator/sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Late exclusion: pyrazinamide resistance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety analysis population included all patients who were randomized (for the DS-TB patients) or assigned (for the MDR-TB patients) to trial medication and who received at least 1 dose of trial medication. Patients were classified according to treatment received.</population>
      <group_list>
        <group group_id="B1">
          <title>DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide</title>
          <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 100 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 4 months during the treatment period (from Day 1 to Week 17). Patients then entered a follow-up period up to Month 24.</description>
        </group>
        <group group_id="B2">
          <title>DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
          <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 4 months during the treatment period (from Day 1 to Week 17). Patients then entered a follow-up period up to Month 24.</description>
        </group>
        <group group_id="B3">
          <title>DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
          <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 6 months during the treatment period (from Day 1 to Week 26). Patients then entered a follow-up period up to Month 24.</description>
        </group>
        <group group_id="B4">
          <title>DS-TB: 2 Months HRZE / 4 Months HR</title>
          <description>Patients with DS-TB were randomized to receive 150 mg rifampicin + 75 mg isoniazid + 400 mg pyrazinamide + 275 mg ethambutol combination tablets (HRZE) orally once daily from Weeks 1 to 8 during the treatment period. Patients then received 150 mg rifiampicin + 75 mg isoniazid combination tablets (HR) orally once daily from Weeks 9 to 26 during the treatment period. The daily dose of HRZE and HR was calculated based on patients' weight. Patients then entered a follow-up period up to Month 24.</description>
        </group>
        <group group_id="B5">
          <title>MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
          <description>Patients with MDR-TB received 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 6 months during the treatment period (from Day 1 to Week 26). Patients then entered a follow-up period up to Month 24.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="67"/>
            <count group_id="B4" value="68"/>
            <count group_id="B5" value="13"/>
            <count group_id="B6" value="284"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="275"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population)</title>
        <description>Patients were classified as having a favorable, unfavorable or unassessable status at 12 months from the start of therapy.
A favourable status was a negative culture status at 12 months from start of therapy in patients who had not already been classified as having an unfavorable outcome, and whose last positive culture result was followed by at least 2 negative culture results. Patients with an unfavorable status did not achieve/maintain culture negative status, or previously had culture negative status who following end of treatment (EOT), had 2 positive cultures, or had a positive culture not followed by 2 negative cultures, or were dying from any cause during treatment (except accidental cause not including suicide), or were dying from TB related causes during follow-up, or required an extension, restart or change of treatment except for reinfection/pregnancy, or failed to complete adequate treatment who were unassessable at 12 months or lost to follow-up/withdrawn before EOT.</description>
        <time_frame>From Day 1 to Month 12.</time_frame>
        <population>The MITT population included all randomized patients excluding late screening failures, lost to follow-up/withdrawn patients who were culture negative, pregnancy, accidental death during treatment, death during follow-up without TB relapse evidence, re-infection with new TB strain + missing/contaminated Month 12 sputum sample.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide</title>
            <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 100 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 4 months during the treatment period (from Day 1 to Week 17). Patients then entered a follow-up period up to Month 24.</description>
          </group>
          <group group_id="O2">
            <title>DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
            <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 4 months during the treatment period (from Day 1 to Week 17). Patients then entered a follow-up period up to Month 24.</description>
          </group>
          <group group_id="O3">
            <title>DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
            <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 6 months during the treatment period (from Day 1 to Week 26). Patients then entered a follow-up period up to Month 24.</description>
          </group>
          <group group_id="O4">
            <title>DS-TB: 2 Months HRZE / 4 Months HR</title>
            <description>Patients with DS-TB were randomized to receive 150 mg rifampicin + 75 mg isoniazid + 400 mg pyrazinamide + 275 mg ethambutol combination tablets (HRZE) orally once daily from Weeks 1 to 8 during the treatment period. Patients then received 150 mg rifiampicin + 75 mg isoniazid combination tablets (HR) orally once daily from Weeks 9 to 26 during the treatment period. The daily dose of HRZE and HR was calculated based on patients' weight. Patients then entered a follow-up period up to Month 24.</description>
          </group>
          <group group_id="O5">
            <title>MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
            <description>Patients with MDR-TB received 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 6 months during the treatment period (from Day 1 to Week 26). Patients then entered a follow-up period up to Month 24.
Note: The MDR-TB group was not randomized and not included in the analysis population.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population)</title>
          <description>Patients were classified as having a favorable, unfavorable or unassessable status at 12 months from the start of therapy.
A favourable status was a negative culture status at 12 months from start of therapy in patients who had not already been classified as having an unfavorable outcome, and whose last positive culture result was followed by at least 2 negative culture results. Patients with an unfavorable status did not achieve/maintain culture negative status, or previously had culture negative status who following end of treatment (EOT), had 2 positive cultures, or had a positive culture not followed by 2 negative cultures, or were dying from any cause during treatment (except accidental cause not including suicide), or were dying from TB related causes during follow-up, or required an extension, restart or change of treatment except for reinfection/pregnancy, or failed to complete adequate treatment who were unassessable at 12 months or lost to follow-up/withdrawn before EOT.</description>
          <population>The MITT population included all randomized patients excluding late screening failures, lost to follow-up/withdrawn patients who were culture negative, pregnancy, accidental death during treatment, death during follow-up without TB relapse evidence, re-infection with new TB strain + missing/contaminated Month 12 sputum sample.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Favorable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unfavorable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was assessed using the upper bound of the two-sided 95% confidence interval (CI) for the difference between the percentage of patients who are classified as having an unfavourable status on the intervention (6 months moxifloxacin + 200 mg PA-824 + pyrazinamide) and the control regimen (2 months HRZE/ 4 months HR). The intervention was considered to be non-inferior to the control arm if the upper bound 95% CI was &lt; 12%.</non_inferiority_desc>
            <param_type>Treatment difference: unfavourable rate</param_type>
            <param_value>9.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.13</ci_lower_limit>
            <ci_upper_limit>23.89</ci_upper_limit>
            <estimate_desc>(DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide) - (DS-TB: 2 Months HRZE/ 4 Months HR).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population)</title>
        <description>Patients were classified as having a favorable, unfavorable or unassessable status at 12 months from the start of therapy.
A favourable status was a negative culture status at 12 months from start of therapy in patients who had not already been classified as having an unfavorable outcome, and whose last positive culture result was followed by at least 2 negative culture results. Patients with an unfavorable status did not achieve/maintain culture negative status, or previously had culture negative status who following EOT, had 2 positive cultures, or had a positive culture not followed by 2 negative cultures, or died from any cause during treatment (except accidental cause not including suicide), or were dying from TB related causes during follow-up, or required a restart or change of treatment because of an unfavorable outcome with or without bacteriological confirmation, ie, on bacteriological, radiographic or clinical grounds.</description>
        <time_frame>From Day 1 to Month 12.</time_frame>
        <population>The PP population consisted of the MITT population, excluding patients who were lost to follow-up/withdrawn, had modified/extended treatment for reasons other than unfavourable therapeutic response, did not receive adequate amount of allocated study regimen and patients with major protocol deviations, unless already classified as unfavourable.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide</title>
            <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 100 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 4 months during the treatment period (from Day 1 to Week 17). Patients then entered a follow-up period up to Month 24.</description>
          </group>
          <group group_id="O2">
            <title>DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
            <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 4 months during the treatment period (from Day 1 to Week 17). Patients then entered a follow-up period up to Month 24.</description>
          </group>
          <group group_id="O3">
            <title>DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
            <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 6 months during the treatment period (from Day 1 to Week 26). Patients then entered a follow-up period up to Month 24.</description>
          </group>
          <group group_id="O4">
            <title>DS-TB: 2 Months HRZE / 4 Months HR</title>
            <description>Patients with DS-TB were randomized to receive 150 mg rifampicin + 75 mg isoniazid + 400 mg pyrazinamide + 275 mg ethambutol combination tablets (HRZE) orally once daily from Weeks 1 to 8 during the treatment period. Patients then received 150 mg rifiampicin + 75 mg isoniazid combination tablets (HR) orally once daily from Weeks 9 to 26 during the treatment period. The daily dose of HRZE and HR was calculated based on patients' weight. Patients then entered a follow-up period up to Month 24.</description>
          </group>
          <group group_id="O5">
            <title>MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
            <description>Patients with MDR-TB received 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 6 months during the treatment period (from Day 1 to Week 26). Patients then entered a follow-up period up to Month 24.
Note: The MDR-TB group was not randomized and not included in the analysis population.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population)</title>
          <description>Patients were classified as having a favorable, unfavorable or unassessable status at 12 months from the start of therapy.
A favourable status was a negative culture status at 12 months from start of therapy in patients who had not already been classified as having an unfavorable outcome, and whose last positive culture result was followed by at least 2 negative culture results. Patients with an unfavorable status did not achieve/maintain culture negative status, or previously had culture negative status who following EOT, had 2 positive cultures, or had a positive culture not followed by 2 negative cultures, or died from any cause during treatment (except accidental cause not including suicide), or were dying from TB related causes during follow-up, or required a restart or change of treatment because of an unfavorable outcome with or without bacteriological confirmation, ie, on bacteriological, radiographic or clinical grounds.</description>
          <population>The PP population consisted of the MITT population, excluding patients who were lost to follow-up/withdrawn, had modified/extended treatment for reasons other than unfavourable therapeutic response, did not receive adequate amount of allocated study regimen and patients with major protocol deviations, unless already classified as unfavourable.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Favorable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unfavorable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was assessed using the upper bound of the two-sided 95% CI for the difference between the percentage of patients who are classified as having an unfavourable status on the intervention (6 months moxifloxacin + 200 mg PA-824 + pyrazinamide) and the control regimen (2 months HRZE/ 4 months HR). The intervention was considered to be non-inferior to the control arm if the upper bound 95% CI was &lt; 12%.</non_inferiority_desc>
            <param_type>Treatment difference: unfavourable rate</param_type>
            <param_value>6.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.15</ci_lower_limit>
            <ci_upper_limit>15.40</ci_upper_limit>
            <estimate_desc>(DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide) - (DS-TB: 2 Months HRZE/ 4 Months HR).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent adverse events were collected from Day 1 up to and including 14 days after the last administration of trial medication (up to a maximum of 28 weeks).</time_frame>
      <desc>The Safety analysis population included all patients in the randomized/assigned to trial medication population set who received at least 1 dose of trial medication. Patients were classified according to treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide</title>
          <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 100 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 4 months during the treatment period (from Day 1 to Week 17). Patients then entered a follow-up period up to Month 24.</description>
        </group>
        <group group_id="E2">
          <title>DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
          <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 4 months during the treatment period (from Day 1 to Week 17). Patients then entered a follow-up period up to Month 24.</description>
        </group>
        <group group_id="E3">
          <title>DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
          <description>Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 6 months during the treatment period (from Day 1 to Week 26). Patients then entered a follow-up period up to Month 24.</description>
        </group>
        <group group_id="E4">
          <title>DS-TB: 2 Months HRZE/ 4 Months HR</title>
          <description>Patients with DS-TB were randomized to receive 150 mg rifampicin + 75 mg isoniazid + 400 mg pyrazinamide + 275 mg ethambutol combination tablets (HRZE) orally once daily from Weeks 1 to 8 during the treatment period. Patients then received 150 mg rifiampicin + 75 mg isoniazid combination tablets (HR) orally once daily from Weeks 9 to 26 during the treatment period. The daily dose of HRZE and HR was calculated based on patients' weight. Patients then entered a follow-up period up to Month 24.</description>
        </group>
        <group group_id="E5">
          <title>MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide</title>
          <description>Patients with MDR-TB received 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 6 months during the treatment period (from Day 1 to Week 26). Patients then entered a follow-up period up to Month 24.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymph node Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Eyelid haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator or any Sub-Investigator shall submit any oral or written publication or abstract concerning this study to the Sponsor not less than thirty (30) days prior to submission to any journal, other publication or meeting for review and removal of confidential information.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Following 3 deaths associated with hepatotoxicity, recruitment was suspended, followed by a partial clinical hold by the United States Food and Drug Association. The hold was removed but the Sponsor permanently stopped recruitment in December 2016.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Leandra Lombard, Director, Clinical Operations</name_or_title>
      <organization>TB Alliance</organization>
      <phone>+27 87 700 3900</phone>
      <email>Leandra.Lombard@tballiance.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

